Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2022-02-01 Epub Date: 2021-10-21 DOI:10.1080/07357907.2021.1988962

Konstantinos Vrontis, Sofia C Economidou, George Fotopoulos

{"title":"Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.","authors":"Konstantinos Vrontis, Sofia C Economidou, George Fotopoulos","doi":"10.1080/07357907.2021.1988962","DOIUrl":null,"url":null,"abstract":"Background: Large Cell Neuroendocrine Carcinoma of the Lung (L-LCNEC) is a rare type of neuroendocrine lung cancer that is increasingly diagnosed. However, the optimal management regarding the advanced stage is unclear. The purpose of this article is to present and compare our experience when L-LCNEC is treated as Small Cell Lung Cancer (SCLC).Patients and methods: Overall, eight cases of L-LCNEC were included. We retrospectively reviewed medical files and reports by accessing the Institution's Data of patients diagnosed with L-LCNEC from April 2019 until December 2020 and evaluated their response to the combination of Platinum - Etoposide - Atezolizumab as first-line chemotherapy.Results: The overall observed response rate (ORR) of 75%. The median PFS was 6.85 months. The median response duration was 5.5 months.Conclusions: Comparing our findings with other retrospective and prospective studies, it seems that the systematic treatment of choice and management in L-LCNEC of the lung should be that of a small cell carcinoma of the lung.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2021.1988962","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/10/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Large Cell Neuroendocrine Carcinoma of the Lung (L-LCNEC) is a rare type of neuroendocrine lung cancer that is increasingly diagnosed. However, the optimal management regarding the advanced stage is unclear. The purpose of this article is to present and compare our experience when L-LCNEC is treated as Small Cell Lung Cancer (SCLC).

Patients and methods: Overall, eight cases of L-LCNEC were included. We retrospectively reviewed medical files and reports by accessing the Institution's Data of patients diagnosed with L-LCNEC from April 2019 until December 2020 and evaluated their response to the combination of Platinum - Etoposide - Atezolizumab as first-line chemotherapy.

Results: The overall observed response rate (ORR) of 75%. The median PFS was 6.85 months. The median response duration was 5.5 months.

Conclusions: Comparing our findings with other retrospective and prospective studies, it seems that the systematic treatment of choice and management in L-LCNEC of the lung should be that of a small cell carcinoma of the lung.

查看原文本刊更多论文

铂双药联合Atezolizumab作为转移性大细胞神经内分泌癌的一线治疗:单一机构经验

背景:肺大细胞神经内分泌癌(L-LCNEC)是一种罕见的神经内分泌肺癌类型，诊断率越来越高。然而，对于晚期阶段的最佳管理尚不清楚。本文的目的是介绍和比较我们将L-LCNEC作为小细胞肺癌(SCLC)治疗的经验。患者和方法:共纳入8例L-LCNEC。我们通过访问该机构2019年4月至2020年12月诊断为L-LCNEC的患者的数据，回顾性地审查了医疗文件和报告，并评估了他们对铂-依托泊苷- Atezolizumab联合化疗作为一线化疗的反应。结果:总观察有效率(ORR)为75%。中位PFS为6.85个月。中位缓解持续时间为5.5个月。结论:将我们的研究结果与其他回顾性和前瞻性研究相比较，似乎L-LCNEC的选择和管理的系统治疗应该是肺小细胞癌。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.